Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 164 HL (TIGERR-HL): Tislelizumab plus Gemcitabine and Cisplatin for Relapsed or Refractory Hodgkin Lymphoma
2022-502225-17-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Hodgkin lymphoma (HL), sponsored by HOVON. Primary endpoint: Progression-free survival probability at 2 years. Planned start Apr 2023; status: authorised.
02
Drugs
tislelizumab
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2022-502225-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502225-17-00.